Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Dong Hee Lee

Vascular Surgery Lexington, KY Medical Doctor

NPI 1396064796 CMS profile 6140094

740 S Limestone, Ste L104, Lexington, KY 40536

Open in the dashboard

General payments

$17,479

200 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Dong Hee Lee of Lexington, KY is reported in the CMS Open Payments database as having received $17,479 across 200 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,570 43
2024 General $1,872 42
2023 General $1,754 29
2022 General $4,285 35
2021 General $954 11
2020 General $1,263 28
2019 General $781 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Dong Hee Lee
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Dong Hee Lee were reported at $6,570. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Dong Hee Lee Vascular Surgery median Middle half National median
2019 $781 $796 $226–$2,363 $163
2020 $1,263 $348 $118–$1,110 $114
2021 $954 $471 $158–$1,421 $132
2022 $4,285 $725 $222–$2,183 $149
2023 $1,754 $836 $257–$2,440 $160
2024 $1,872 $909 $252–$2,619 $164
2025 $6,570 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $3,764 34 payments
  2. Penumbra, Inc. $3,463 13 payments
  3. Silk Road Medical, Inc. $2,115 20 payments
  4. Endologix, Inc. $993 12 payments
  5. Organogenesis Inc. $923 35 payments
  6. Sirtex Medical Inc $883 3 payments
  7. Shockwave Medical, Inc $800 8 payments
  8. W. L. Gore & Associates, Inc. $714 6 payments
  9. Tactile Systems Technology Inc $666 24 payments
  10. Medtronic Vascular, Inc. $465 9 payments
  11. Other $2,694 36 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $12,668 184 payments
  2. Travel and Lodging $4,811 16 payments
Products named General payments · program years 2019–2025
  1. ENDURANT IIS $3,479 31 payments
  2. Indigo System $3,463 13 payments
  3. ENROUTE Transcarotid Stent $1,987 19 payments
  4. ENROUTE Transcarotid Neuroprotection System Cardiology/Vascular Diseases $1,987 19 payments
  5. LAVA LES (Liquid Embolic System) $883 3 payments
  6. ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter $558 6 payments
  7. ENROUTE Transcarotid Neuroprotection System Cardiology/Vascular Diseases $558 6 payments
  8. GORE VIABAHN VBX Balloon Expandable Endo $513 4 payments
  9. ENTRE $480 20 payments
  10. ACTITOUCH $480 20 payments
  11. Other $8,527 137 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

175

Median for Vascular Surgery: 122

Drug cost

$22,782

Median for Vascular Surgery: $14,135

Branded share of claims

58.3%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 33 $21,470
Atorvastatin Calcium Generic 44 $589
Clopidogrel Clopidogrel Bisulfate Brand 54 $329
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 15 $163
Cilostazol Generic 16 $132
Rosuvastatin Calcium Generic 13 $98

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 135 billing codes

Paid by Medicare

$107,166

Medicare's payments for the services billed

Medicare patients

416

Average age 70

Services billed

891

157 women, 259 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Ischemic heart disease 52%
Diabetes 48%
Chronic kidney disease 44%
COPD 42%
Heart failure 40%
Depression 36%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

200 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record